VSTM Q1 2022 Earnings — Verastem, Inc. Revenue & Financial Results | Market Cap Arena

VSTMVerastem, Inc.

$388M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+158.1% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$17M-654.1% margin

Net Income

-$17M-653.4% margin

EPS (Diluted)

$-1.09

QoQ Revenue Growth

+376.3%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$116M

Total Liabilities

$43M

Stockholders' Equity

$73M

Cash & Equivalents

$47M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$1M	+158.1%
Gross Profit	$3M	$1M	+158.1%
Operating Income	-$17M	-$14M	-20.4%
Net Income	-$17M	-$15M	-12.8%

Revenue Segments

Sale of COPIKTRA license and related assets

$3M100%